[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"resectable-pancreatic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:resectable-pancreatic-cancer":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,71,94,117,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100594635","predictive-risk-factors-for-pancreatic-fistula-after-pancreaticoduodenectomy-100594635",false,"NCT07022015","Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy","Predictive Risk Factors for Postoperative Pancreatic Fistula After Pancreaticoduodenectomy for Malignancy.","POPF","Inclusion Criteria:\n\n* Patients with resectable distal common bile duct carcinoma, periampullary carcinoma, duodenal carcinoma, and carcinoma of the head of the pancreas.\n* Patients meeting the curative treatment intent in accordance with clinical guidelines:\n\n  * No evidence of metastasis.\n  * Radiological non-involvement of superior mesenteric vein \\& portal vein.\n* American Society of Anesthesiologists (ASA) scores I \\& II.\n* Patients aged \\> 18 years.\n* Ability to understand and the willingness to sign a written informed consent document\n* Agreement to complete the study\n\nExclusion Criteria:\n\n* Unfit patients for surgery due to severe medical illness.\n* Inoperable patients with distant metastases, including peritoneal, liver, distant lymph node metastases, and involvement of other organs.\n* Irresectable tumors in diagnostic laparoscopy.\n* History of other malignant disease.\n* Pregnant or breast-feeding women.\n* Patients with serious mental disorders.\n* Patients with vascular invasion and requiring vascular resection as evaluated by the multidisciplinary team according to abdominal imaging data.\n* Pancreatoduodenectomy for other diagnosis like cystic lesions, benign tumors or chronic calcific pancreatitis\n* Patients refused to participate in the study.","ALL","18 Years","75 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","Pancreaticoduodenectomy (PD) is a complex procedure performed in patients with malignant or benign tumors of the pancreatic head and periampullary region, associated with high morbidity and mortality. Postoperative pancreatic fistula (POPF) is the most common and clinically significant complication following PD. In this study, the investigators aim to determine the predictive risk factors for clinically related postoperative pancreatic fistula (CR-POPF) in the preoperative, intraoperative and postoperative period in patients that underwent PD. The total number of 100 participants expected to be included in this research who underwent PD between 2025 and 2026.",[28,29,30,31,32,33,34],"Pancreas Cancer","Pancreas Neoplasm","Pancreatic Fistula","Pancreas Adenocarcinoma","Periampullary Cancer","Periampullary Carcinoma","Resectable Pancreatic Cancer","RECRUITING","2026-06-27",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":39},"2025-06-20",{"date":43,"type":22},"2026-10-20",{"name":45,"class":46},"Minia University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":47},"100487271","phase-2-a-study-of-novottf-200tp-in-combination-with-gemcitabine-and-nab-paclitaxel-for-resectable-pancreatic-adenocarcinoma-100487271","NCT05624918","A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma","A Phase II Study of Peri-Operative NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n-Written informed consent and HIPAA authorization for release of personal health information.\n\nNOTE: HIPAA authorization may be included in the informed consent or obtained separately.\n\n* Male or non-pregnant, non-lactating female age ≥ 18 years at the time of consent.\n* Karnofsky Performance Status (KPS) of ≥70% within 7 days prior to registration.\n* Histological or cytological evidence of pancreatic adenocarcinoma.\n* Patients must have resectable primary tumor per NCCN definitions version 2.2021 based on contrast-enhanced CT or MRI (CT or MRI without contrast as part of PET\u002FCT or PET\u002FMRI is NOT acceptable; CT or MRI with contrast as part of PET\u002FCT or PET\u002FMRI is acceptable) of the chest, abdomen, and pelvis, where resectable is defined as all of the following:\n\n  * No involvement of the celiac artery, common hepatic artery, and superior mesenteric artery (and, if present, replaced right hepatic artery).\n  * No involvement, or \\\u003C 180° interface between tumor and vessel wall, of the portal vein and\u002For superior mesenteric vein; and patent portal vein\u002Fsplenic vein confluence.\n  * No evidence of metastatic disease. NOTE: To minimize ineligible patients, an institutional checklist, identical to the one used by the central radiologist at the end of the study, will be mandated for completion by the enrolling site investigator or radiologist. The 6-point checklist will include visible pancreatic mass; measurable disease; absence of arterial interface; venous interface of less than or equal to 180°; patent portal-splenic confluence; and absence of metastatic disease, including lymphadenopathy outside the surgical basin.\n* Measurable disease according to RECIST v1.1 for solid tumors within 28 days prior to registration.\n* Patients must not have received prior surgery, radiation therapy, chemotherapy, targeted therapy, or any investigational therapy for pancreatic cancer.\n* Demonstrate adequate organ function as defined in the table below; all screening labs to be obtained within 28 days prior to registration.\n\n  * Hematological\n\n    * Absolute Neutrophil Count (ANC) ≥ 1.5 K\u002Fmm3\n    * Hemoglobin (Hgb) ≥ 8.0 g\u002FdL\n    * Platelets ≥100,000\u002Fmm3\n  * Renal\n\n    ---Calculated creatinine clearance ≥ 30 cc\u002Fmin using the Cockcroft-Gault formula\n  * Hepatic\n\n    * Bilirubin ≤ 1.5 × upper limit of normal (ULN)\n    * Aspartate aminotransferase (AST) ≤ 3 × ULN\n    * Alanine aminotransferase (ALT) ≤ 3 × ULN\n* Females of childbearing potential must have a negative pregnancy test (serum or urine) within 3 days prior to registration. See the protocol for definition of childbearing potential.\n* Females of childbearing potential must be willing to abstain from vaginal intercourse or use an effective method(s) of contraception from the time of informed consent, during the study, and for 6 months after the last dose of study drug(s). Males must be willing to abstain from vaginal intercourse or to use an effective method(s) of contraception from initiation of treatment, during the study, and for 3 months after the last dose of study drug(s). See also the protocol (contraception).\n* As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study\n* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial.\n* Patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, the HCV viral load must be undetectable to be eligible for this trial.\n\nExclusion Criteria:\n\n* Evidence of distant metastasis\n* Patients with an electrical implantable device in the torso. Examples of electrical implanted medical devices include spinal cord stimulators, vagus nerve stimulators, pacemakers, and defibrillators.\n* History of significant uncontrolled cardiovascular disease. Significant cardiac disease includes second\u002Fthird degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary activity results in fatigue, palpitation or dyspnea).\n* History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the trial -Known allergy to medical adhesives or conductive hydrogel (gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes).\n* Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).\n* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are not eligible for this trial.\n* Patient has any other concurrent severe and\u002For uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol: (e.g., chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.)\n* No prior malignancy is allowed except for adequately treated basal (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the patient has been disease and treatment-free for two years.\n* Patient is unwilling or unable to comply with study procedures.",{"count":56,"type":22},38,[58],"PHASE2","This is a single arm phase II study. All patients will receive 3 cycles of the treatment of nab-paclitaxel (Days 1, 8 and 15), gemcitabine (Days 1, 8 and 15), and TTFields (worn every day for at least 18 hours). Following the initial 3 cycles of gemcitabine\u002Fnab-paclitaxel\u002FTTFields treatment, patients will undergo restaging by CT or MRI. Patients with stable disease or better will undergo surgery for resection within 8 weeks following completion of initial chemotherapy although enrolling sites are encouraged to perform resection within 4 weeks of Cycle 3 D15 of therapy. If resection yields R0 or R1, patients will begin an additional 3 cycles of gemcitabine\u002Fnab-paclitaxel\u002FTTFields treatment within 8 weeks of surgery. Based on available literature, it is expected that a percentage of patients will not undergo resection either due to disease progression or due to toxicities\u002F complications of the neoadjuvant segment of therapy. These patients will be included in the evaluable patients for both co-primary endpoints as well as the secondary endpoints including ORR, adverse events, and OS.",[61,34],"Pancreatic Adenocarcinoma","2026-04-02",{"date":64,"type":39},"2026-04-08",{"date":66,"type":39},"2024-07-01",{"date":68,"type":22},"2028-08-29",{"name":70,"class":46},"Ashish Manne",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100499860","implementing-ctdna-and-circular-dna-in-patients-with-localized-pancreatic-cancer-100499860","NCT05788744","Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer","Implementing Non-invasive Circulating Tumor DNA and Circular DNA Analysis in Patients With Localized Pancreatic Cancer to Optimize the Pre- and Postoperative Treatment: Predicting Recurrence and Survival and Changing Prognosis Over Time","CIRCPAC","Inclusion Criteria:\n\n* Sub-study 1: Suspicion of PDAC tumor stage I-III, scheduled for pancreatic resection, with or without preoperative neoadjuvant chemotherapy.\n* Sub-study 2: .\n\n  * PDAC tumor stage I-III\n  * Has received intended curative resection (R0\u002FR1) of PDAC\n  * No signs of local recurrence or metastatic disease at a CT scan 4 months after the operation\n\nExclusion Criteria:\n\n* Other cancers (excluding skin cancer other than melanoma) later than 3 years before inclusion\n* Patients who are unlikely to comply with the protocol, inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study",{"count":80,"type":22},1000,[25],"The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if plasma ctDNA combined with CT scan and endoscopic ultrasound surveillance increases the median overall survival compared with standard-of-care surveillance.",[34],"2026-03-24",{"date":86,"type":39},"2026-03-27",{"date":88,"type":39},"2023-01-01",{"date":90,"type":22},"2032-01",{"name":92,"class":46},"Copenhagen University Hospital at Herlev",5,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":47},"100323570","phase-2-testing-the-combination-of-two-approved-chemotherapy-drugs-and-radiation-prior-to-surgery-in-localized-pancreatic-cancer-100323570","NCT03492671","Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer","A Phase II Trial of Pre-operative Chemotherapy (With Gemcitabine and Nab- Paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients With Resectable Pancreatic Adenocarcinoma","Inclusion Criteria (all criteria must apply):\n\n* Cytologic or histologic proof of adenocarcinoma of the pancreas.\n* Localized, potentially resectable tumors.\n* Greater or equal to 18 years of age.\n* ECOG performance status of 0 or 1.\n* Adequate hematologic, renal and hepatic function as defined by:\n* ANC greater or equal to 1,500 cells\u002Fmm3\n* Platelets greater or equal to 100,000 cells\u002Fmm3\n* Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)\n* Serum creatinine ≤ 2 x ULN • ALT ≤ 5 x ULN\n* AST ≤ 5 x ULN\n* No history of prior therapy for pancreatic cancer.\n* No history of active infection requiring IV antibiotics at the start of study treatment\n* Non-pregnant and non-breast-feeding.\n\nExclusion Criteria:\n\n* Patient has borderline resectable or metastatic disease.\n* History of malignancy in the last 5 years other than in situ cancer or basal or squamous cell skin cancer or malignancies cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years.\n* Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.",{"count":102,"type":22},30,[58],"The purpose of this phase 2 research study is to determine whether a combination of chemotherapy drugs plus radiation therapy, given before surgery in resectable pancreactic cancer, can help to increase the chances of surgeons achieving and R0 resection. The chemotherapy drugs used are gemcitabine and nab-paclitaxel. These drugs are both approved by the FDA for use in treating adults with pancreatic adenocarcinoma. The investigational portion of this study is providing the chemotherapy drugs and radiation therapy before surgery. Primary Endpoint, R) resection rate ≥70%. Secondary Endpoints, Disease free survival, Overall survival , Perioperative mortality and morbidity.",[31,34],[107],"Pancreatic Cancer","2025-09-30",{"date":110,"type":39},"2025-10-02",{"date":112,"type":39},"2019-07-17",{"date":114,"type":22},"2026-09",{"name":116,"class":46},"Loma Linda University",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},"100479973","phase-3-neofol-r-trial-perioperative-versus-adjuvnat-folfirinox-in-resectable-pancreatic-cancer-100479973","NCT05529940","NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)","Efficacy of Perioperative Versus Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: an International Multicenter Randomized Controlled Trial (NeoFOL-R Trial)","Inclusion Criteria:\n\n\\- A. Age: 19 to 80 years old B. Patients with a score of 0 - 1 (ECOG) when selecting a study subject C. Pancreatic ductal adenocarcinoma diagnosed by histological examination (histologic or cytopathological) D. Patients evaluated as resectable pancreatic cancer in preoperative imaging as follows (NCCN guidelines for pancreatic adenocarcinoma version 2.2021)\n\n* No arterial tumor contact (celiac asix, superior mesenteric artery, or common hepatic artery).\n* No tumor contact with the superior mesenteric vein or portal vein or ≤ 180°contact without vein contour irregularity.\n\nE. No distant metastases on preoperative imaging F. Patients with adequate organ function\n\n1. Bone marrow function: WBC 3,000\u002Fmm3 or more or ANC 1,500\u002Fmm3 or more, platelet ≥ 100K\u002Fmm3\n2. Liver function: Bilirubin ≤ 3 x upper normal limit (≤5.0 mg\u002FdL), AST\u002FALT ≤ 5 x upper normal limit (\\\u003C200 IU\u002FL)\n3. Renal function (Cr clearance ≥ 60 mL\u002Fmin) or (Cr \\\u003C 1.5 x upper normal limit) G. Persons physically capable of undergoing surgery H. Those who consented to the clinical trial I. Women of childbearing potential must have a negative serum pregnancy test within one week before starting the intervention drug. Men and women of childbearing potential must use effective contraception from screening through six months after the last dose.\n\nExclusion Criteria:\n\n\\- Patients who met any of the following criteria are not eligible to participate in this study.\n\nA. Those evaluated as borderline resectable or locally advanced pancreatic cancer in preoperative imaging examination (The resectability assessment depends on the presence of major vessel invasion, while invasion of adjacent organs is excluded from the criteria) B. Patients with a history of previous pancreatic surgery C. Patients with a history of previous chemotherapy or radiation therapy for pancreatic cancer D. Patients with distant metastases or recurrent pancreatic cancer E. Pancreatic body or tail cancer requiring combined resection of adjacent organs (stomach or kidney) (except for the adrenal gland) F. Patients within five years of diagnosis of other organ malignancies (with the exception of adequately treated non-melanoma skin cancer and carcinoma in situ without evidence of disease) G. Pregnant and lactating women H. Serious concomitant systemic disorders, including active or ongoing systemic infections, symptomatic congestive heart failure, unstable angina, clinically significant cardiac arrhythmias, psychiatric disorders, or uncontrolled comorbid conditions that may limit compliance with study requirements, or any medical condition that, at the discretion of the investigator, could compromise patient safety, interfere with the assessment of safety and efficacy, or hinder participation in the clinical trial.","19 Years","80 Years",{"count":127,"type":22},609,[129],"PHASE3","Rationale: Adjuvant chemotherapy after surgery significantly improved the survival of PC patients, but there is a problem that only about 50% of patients start adjuvant chemotherapy after pancreatectomy. Neoadjuvant chemotherapy might control potential metastatic lesion which are not being detected in early diseases status and improve the R0 resection rate. In addition, it prevents futile surgery by selecting patients with rapid progression of disease. Furthermore, compared to chemotherapy administered after surgery, more patients can complete the planned chemotherapy schedule in neoadjuvant setting. Asians differ from Westerners not only in racial differences, but also in average size and body surface area. Accordingly, there is an urgent need for clinical studies on the dose, toxicity, dosing cycle, and efficacy of anticancer drugs that reflect actual clinical trials in Asian countries for Asians. There are still few studies worldwide that prospectively explored the efficacy of neoadjuvant chemotherapy in resectable PC and the administration of neoadjuvant therapy in resectable PC depends on individual clinical judgment. Therefore, systematic and prospective clinical trials are essential to standardize treatment protocol in resectable PC.\n\nObective: To investigate whether 6 cycles of preoperative mFOLFIRINOX - surgery - 6 cycles of postoperative mFOLFIRINOX improves overall survival by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.\n\nStudy design: open-label, multicenter, randomized, phase 3 clinical trial Study population: Patients with resectable pancreatic cancer and ECOG performance 0 or 1.\n\nIntervention:\n\nInvervention arm : 6 cycles of neoadjuvant mFOLFIRINOX followed by surgical resection and 6 cycles of adjuvant mFOLFIRINOX Comparator arm : surgical resection followed by 12 cycles of adjuvant mFOLFIRINOX Primary endpoint: 2-year overall survival rate by intention-to-treat",[34,132,133],"Neoadjuvant Chemotherapy","Effects of Chemotherapy","2024-11-25",{"date":136,"type":39},"2024-11-27",{"date":138,"type":39},"2023-04-01",{"date":140,"type":22},"2027-12",{"name":142,"class":46},"Seoul National University Hospital",2,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":23,"phases":154,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100529304","phase-2-irinotecan-liposome-for-resectable-pancreatic-cancer-with-or-without-addebelizumab-100529304","NCT06172036","Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab","A Multicenter, Multi-cohort, Randomized, Phase II Study of Irinotecan Liposome Combined With 5-FU \u002F LV and Oxaliplatin for Resectable Pancreatic Cancer With or Without Addebelizumab","CAPT-02","Inclusion Criteria:\n\n1. Age: 18 years old, male or female;\n2. According to the NCCN clinical practice guidelines (2023.V2 version), multidisciplinary and imaging evaluation for patients with resectable pancreatic cancer, resectable defined as: by imaging examination, the criteria of radical resection of tumor is no distant metastasis, the artery (trunk celiac, superior mesenteric artery or common hepatic artery), and the tumor did not invade the superior mesenteric vein and portal vein, or invasion but not more than 180 and the venous contour is normal.\n3. Have not received any anti-tumor therapy (including radiotherapy, ablation, chemotherapy, targeted therapy, immunotherapy, etc.) or research drug therapy; 4. At least one measurable lesion must be used as the target lesion (according to the RECIST v1.1 criteria);\n\n5\\. ECOG：0～1； 6. Expected survival period of 3 months; 7. Main organ function, meeting the following criteria (without receiving any blood components, cell growth factors within the 14 days prior to randomization):\n\n1. Neutrophils 1.5 \\* 109 \u002F L; platelets 80 \\* 109 \u002F L; 9 g\u002Fdl hemoglobin and 3 g\u002Fdl serum albumin;\n2. The upper limit of total bilirubin is 1.5 times (biliary obstruction allows biliary drainage); the upper limit of ALT and AST is 3 times (for patients of liver metastasis, it can be relaxed to 5 times the upper limit of normal);\n3. The upper limit of normal serum creatinine is 1.5 times, and the creatinine clearance is 60ml \u002F min;\n4. The upper limit of INR is 1.5 times and the upper limit of APTT is 1.5 times (for stable doses of anticoagulant therapy such as low molecular weight heparin or warfarin and INR can be screened within the expected treatment range of anticoagulant);\n5. ECG: QTcF 450ms (male), 470ms (female);\n6. Cardiac color ultrasound: LVEF (left ventricular ejection fraction) 50%; 8. Women of childbearing age must have a negative blood pregnancy test within 3 days before randomization and be willing to use appropriate contraception during the trial and within 6 months of treatment. For men, it should be surgical sterilization, or consent to use appropriate methods of contraception during the study period and within 3 months after the end of treatment; 9. Subjects volunteered to join the study and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with pancreatic cancer arising from non-pancreatic ductal epithelium, including pancreatic neuroendocrine carcinoma, pancreatic acinar cell carcinoma, pancreatic pancreoblastoma, and solid-pseudopapillary tumors;\n2. Patients with known central nervous system metastases;\n3. Severe gastrointestinal dysfunction (bleeding, obstruction; inflammation greater than grade 2; diarrhea greater than grade 1);\n4. Within 2 weeks before randomization, the third space effusion (such as a large amount of pleural fluid) (no intervention after removing the drainage tube);\n5. Patients with clinical symptoms of ascites, requiring puncture, drainage, who have received ascites drainage within the previous 3 months (only a small amount of ascites on imaging and controllable, except those without clinical symptoms);\n6. Current subjects with interstitial pneumonia or interstitial lung disease, or a history requiring hormonal therapy, or other pulmonary fibrosis, mechanical pneumonia (e. g., bronchiolitis obliterans), pneumoconiosis, drug-related pneumonia, idiopathic pneumonia, idiopathic pneumonia or active CT during screening that may interfere with the judgment and management of immune-related pulmonary toxicity; active tuberculosis;\n7. Patients with active autoimmune disease or a history of autoimmune disease that may relapse \\[including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, optis, enteritis, vasculitis, nephritis, hyperthyroidism, reduced thyroid function (only controlled by hormone replacement therapy can be enrolled)\\]; skin diseases without systemic treatment, such as vitiligo, psoriasis, alopecia, controlled type I diabetes or asthma in childhood has been completely alleviated in adults without any intervention;\n8. Known peripheral neuropathy (CTCAE Grade 3);\n9. Known dihydropyrimidine dehydrogenase (low activity) or deficiency;\n10. Severe infection (CTCAE\\> 2), such as severe pneumonia, bacteremia, infectious complications, requiring hospitalization, occurred within 4 weeks of randomization; symptoms and signs of infection within 2 weeks of randomization (except in cases of prophylactic antibiotics);\n11. Received any of the following treatments:\n\n(1)Concomitant medication containing CYP3A4, CYP2C8 strong inhibitor \u002F strong inducer or strong UGT1A1 inhibitor within 2 weeks before randomization; (2)Immunosuppressants or systemic hormone therapy within 2 weeks prior to randomization to achieve immunosuppressive purposes (dose\\> 10mg prednisone \u002F day or other efficacy hormones); (3)Received radiation therapy within 2 weeks before randomization; (4)Receiving major surgery (such as thoracotomy, laparotomy, etc.) within 4 weeks before randomization; (5)Have received any other clinical study drug treatment within 4 weeks before randomization, except for an observational (non-interventional) clinical study or interventional clinical study follow-up.\n\n12\\. Abnormal coagulation, bleeding tendency or undergoing thrombolytic or anticoagulant therapy. Prophylactic use of low-dose aspirin (100mg \u002F day), low molecular weight heparin (enoxaparin 40mg \u002F day and other low molecular weight heparin at its equivalent doses) is allowed; 13. cardiac clinical symptoms or diseases that are not well controlled, such as: (1) heart failure; (2) unstable angina; (3) myocardial infarction within 6 months; (4) patients with clinically significant supraventricular or ventricular arrhythmias who need treatment or intervention; 14. Malignant tumors other than pancreatic cancer within 5 years before randomization, except for adequately treated cervical carcinoma in situ, skin basal cell, or squamous epithelial cell carcinoma; 15. Those known to be allergic to PD-L1, irinotecan liposomal, other liposomal products, oxaliplatin, 5-FU, leucovorin and any of the components of the above products; 16. Those known to have acquired immune deficiency syndrome (AIDS) or HIV test positive, active syphilis; 17. A clear past history of neurological or psychiatric disorders, including epilepsy or dementia; 18. By the judgment of the investigator, the subject has other factors that may be forced to terminate the study, such as non-compliance protocol, with other serious diseases (including mental illness) need to combine treatment, clinical significant laboratory value seriously abnormal, family or social factors, may affect the safety or trial data collection of subjects.",{"count":153,"type":22},180,[58],"To evaluate the efficacy and safety of irinotecan liposomes with oxaliplatin, 5-fluorouracil (5-FU) \u002F leucovorin (LV) with or without adelizumab for resectable pancreatic cancer by assessing the 12-month EFS rate",[132,34],[158,159,160],"resectable pancreatic cancer","irinotecan liposomes","Adebellizumab","NOT_YET_RECRUITING","2023-12-14",{"date":164,"type":39},"2023-12-15",{"date":166,"type":22},"2024-01-20",{"date":168,"type":22},"2027-01-20",{"name":170,"class":46},"Zhejiang University"]